NCT06491940

Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan

Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan on Proteinuria in Diabetic Nephropathy Patients

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 234 (estimated)
• Sponsor: RESnTEC, Institute of Research · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage. However, the addition of a diuretic like hydrochlorothiazide may offer synergistic benefits in reducing proteinuria by addressing both the underlying renal pathology and potential volume overload in these patients. The current study aims at determining and comparing the role of losartan alone vs hydrochlorothiazide plus losartan in reducing proteinuria in diabetic nephropathy patients.

Conditions

• Proteinuria

Interventions

Type	Name	Description
DRUG	Losartan	Patients will receives Losartan (LS) 50 mg per day.
DRUG	Losartan + Hydrochlorothiazide	Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.

Timeline

• Start date: 2024-08-01
• Primary completion: 2025-07-31
• Completion: 2025-07-31
• First posted: 2024-07-09
• Last updated: 2024-07-09

Locations

1 site across 1 country: Pakistan